Europe's Drug Watchdog Concludes Possible Link Between AstraZeneca COVID-19 Vaccine And Blood Clots
Europe's Drug Watchdog Concludes Possible Link Between AstraZeneca COVID-19 Vaccine And Blood Clots
The European Medicines Agency (EMA), after an in-depth analysis, has concluded that unusual blood clots should be listed as a “very rare side effect” of the Oxford/AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine.
What Happened: The EMA’s safety committee said that it considered all the available evidence around the instances of unusual blood clots with low blood platelets in people who received AstraZeneca’s shot. However, the agency confirms that the overall benefit-risk remains positive.
The EMA said most of the blood clot cases reported have occurred in women under 60 years of age within two weeks of their first vaccine dose. However, the specific risk factors have not yet been confirmed.
“A plausible explanation for these rare side events is an immune response to the vaccine similar to one seen in patients treated with heparin,” called heparin-induced thrombocytopenia, noted the agency.
The EMA said people who have received this vaccine should “seek medical assistance immediately” if they develop symptoms of this combination of blood clots and low blood platelets.
Why It Matters: In an interview with Italian newspaper Il Messaggero published Tuesday, Marco Cavaleri, chair of the EMA’s vaccine evaluation team, said: “In my opinion, we can now say it, it is clear that there is an association with the vaccine. However, we still do not know what causes this reaction.”
Last month, EMA said that it had found the AZN shot safe and effective but added if a connection between the clots and the vaccine is established, the EMA will change its recommendations.
Today, Reuters reported that several European countries are looking at a mix of COVID-19 vaccine doses for people who have received the first dose of AstraZeneca shot amid the crisis.
Price Action: AZN shares dropped 0.4% at $49.03 during the market trading hours on the last check Wednesday.
The European Medicines Agency (EMA), after an in-depth analysis, has concluded that unusual blood clots should be listed as a “very rare side effect” of the Oxford/AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine.
歐洲藥品管理局(EMA)在經過深入分析後得出結論，不尋常的血液凝塊應該被列為牛津大學的“非常罕見的副作用”。阿斯利康(AstraZeneca Plc)(納斯達克股票代碼：AZN)新冠肺炎疫苗。
What Happened: The EMA’s safety committee said that it considered all the available evidence around the instances of unusual blood clots with low blood platelets in people who received AstraZeneca’s shot. However, the agency confirms that the overall benefit-risk remains positive.
發生的事情：EMA的安全委員會表示，他們考慮了所有可獲得的證據，證明接受阿斯利康注射的人出現了不尋常的血液凝塊和低血小板。然而，該機構證實，總體收益-風險仍然是積極的。
The EMA said most of the blood clot cases reported have occurred in women under 60 years of age within two weeks of their first vaccine dose. However, the specific risk factors have not yet been confirmed.
EMA説，大多數報告的血栓病例都發生在60歲以下的女性，在她們接種第一劑疫苗後的兩週內。不過，具體的風險因素尚未得到確認。
“A plausible explanation for these rare side events is an immune response to the vaccine similar to one seen in patients treated with heparin,” called heparin-induced thrombocytopenia, noted the agency.
該機構指出：“對於這些罕見的副作用，一個合理的解釋是對疫苗的免疫反應，類似於肝素治療的患者的免疫反應，稱為肝素誘導的血小板減少症。”
The EMA said people who have received this vaccine should “seek medical assistance immediately” if they develop symptoms of this combination of blood clots and low blood platelets.
EMA説，接種過這種疫苗的人如果出現這種血栓和低血小板的組合症狀，應該“立即尋求醫療幫助”。
Why It Matters: In an interview with Italian newspaper Il Messaggero published Tuesday, Marco Cavaleri, chair of the EMA’s vaccine evaluation team, said: “In my opinion, we can now say it, it is clear that there is an association with the vaccine. However, we still do not know what causes this reaction.”
重要的原因：在週二發表的意大利報紙Il Messaggero的採訪中，EMA疫苗評估小組主席馬爾科·卡瓦拉利(Marco Cavalert I)表示：“在我看來，我們現在可以這麼説，很明顯，這與疫苗有關。不過，我們仍不清楚是什麼原因導致了這種反應。“
Last month, EMA said that it had found the AZN shot safe and effective but added if a connection between the clots and the vaccine is established, the EMA will change its recommendations.
上個月，EMA表示，他們發現AZN疫苗是安全有效的，但補充説，如果凝塊和疫苗之間建立了聯繫，EMA將改變其建議。
Today, Reuters reported that several European countries are looking at a mix of COVID-19 vaccine doses for people who have received the first dose of AstraZeneca shot amid the crisis.
今天，路透社報道，幾個歐洲國家正在考慮為接種了第一劑新冠肺炎疫苗的人提供混合劑量的新冠肺炎疫苗。阿斯利康在危機中拍攝的。
Price Action: AZN shares dropped 0.4% at $49.03 during the market trading hours on the last check Wednesday.
價格行動：在週三的最後一次檢查中，AZN股價在市場交易時段下跌0.4%，至49.03美元。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧